Table 2.
EBV miR-BARTs in EBV infected cells or tissues.
| Cluster | miRNA | Target | Target gene function | miRNA effect | Number of patients | In vitro model | References |
|---|---|---|---|---|---|---|---|
| 1 | BART1 | Overexpressed in GC | 59 GC | no | Kang et al., 2017 | ||
| 1 | BART3 | IPO7 | Nuclear importer protein | Immune evasion | no | Human B cell line | Dölken et al., 2010 |
| 1 | BART3 | DICE1 | Tumor suppressor | Increased cell proliferation | 11 NPC | Hela, Hek, GC | Lei et al., 2013 |
| 1 | BART4 | BID | Pro-apoptotic protein | Anti-apoptotic in GC cell lines | 10 GC | GC | Shinozaki-Ushiku et al., 2015 |
| 1 | BART4 | Overexpressed in GC | 59 GC | no | Kang et al., 2017 | ||
| 1 | BART5 | PUMA | Pro-apoptotic protein | Inhibition of apoptosis | 15 NPC | HeLa, HEK, NPC, GC | (Choy et al., 2008) |
| 1 | BART6-5p | DICER | miRNA biogenesis | Unknown | no | LCL, BL, Hek, HeLa | Iizasa et al., 2010 |
| 1 | BART6-3p | LOC553103 | Unknown | Reduced migration and invasion | no | NPC, GC | He et al., 2016 |
| 1 | BART15-3p | BRUCE | Anti-apoptotic | Increased apoptosis | no | GC | Choi et al., 2013 |
| 1 | BART15 | NLPR3 | Regulation of inflammation | Immune evasion | no | Macrophages | Haneklaus et al., 2012 |
| 1 | BART16 | TOMM22 | Mitochondrial receptor for pro-apoptotic protein BAX | Inhibition of apoptosis | no | Human B cells line | Dölken et al., 2010 |
| 1 | BART1-3p + BART16 | CASP3 | Pro-apoptotic | Inhibition of apoptosis | no | BL | Vereide et al., 2013 |
| 1 | BART3 + BART16 | IPO7 | Nuclear importer protein | Immune evasion | no | BL | Vereide et al., 2013 |
| 2 | BART9 | CDH1 | Increased proliferative and invasion activity in SNU719 | 1039 GC | GC | Tsai et al., 2017 | |
| 2 | BART11 | FOXP1 | Promotion of inflammation | no | NPC, GC, MONOCYTES | Song et al., 2016 | |
| 2 | BART13-3p | CAPRIN2 | Wnt-signaling | Inhibition of apoptosis | no | BL | Riley et al., 2012 |
| 2 | BART19-3p | WIF1 | Wnt inhibitor | Deregulation of the canonical Wnt-signaling pathway | 20 NPC | NPC | Wong et al., 2012 |
| 2 | BART19-3p + BART14 + BART18 | NLK | Wnt Inhibitor | Deregulation of the canonical Wnt-signaling pathway | 20 NPC | NPC | Wong et al., 2012 |
| 2 | BART19-3p + BART7 + BART17 | APC | Wnt Inhibitor | Deregulation of the canonical Wnt-signaling pathway | 20 NPC | NPC | Wong et al., 2012 |
| 2 | BART20 | BZLF1, BRLF1* | Viral proteins | no | GC | Jung et al., 2014 | |
| 2 | BART20 | Associated to poor survival | 59 GC | no | Kang et al., 2017 | ||
| 2 | BART20 | BAD | Apoptosis regulator | Inhibition of apoptosis and suppression of lytic induction | no | GC | Kim et al., 2015 |
| BART2 | BALF5* | Viral polymerase | Inhibition of transition from latent to lytic viral replication | no | Hela, BL | Barth et al., 2007 | |
| BART2 | MICB | NK cell ligand | Immune evasion | no | HEK,CC, HeLa, LL | Nachmani et al., 2009 |
*
Viral protein. LCL, lymphoblastoid cell line; BL, Burkitt's lymphoma; GC, gastric cancer; NPC, nasopharyngeal cancer; HEK, Human embryonic kidney cell line; CC, colon carcinoma; LL, lymphoma cell line.